ChromaDex Inc. (NASDAQ: CDXC), a leading bioscience company devoted to healthy aging, is delighted to announce the appointment of Brianna Gerber as its new Chief Financial Officer, effective January 1, 2023. Gerber has been with ChromaDex since 2018, most recently serving as Senior Vice President of Finance and Interim CFO since August 11, 2022. ChromaDex is confident that Gerber will help lead the company to greater success in the years to come.
With over two decades of expertise in the fields of investment management, investor relations, and finance, Gerber has a proven track record of success in implementing strategic plans, optimizing operational efficiency, and managing capital market transactions.
We are thrilled to kick off 2021 with the news of Brianna’s appointment as our new Chief Financial Officer! Brianna is an invaluable asset to ChromaDex as we strive for EBITDA positivity and financial responsibility. Her leadership, business acumen, and operational experience have been instrumental in driving positive results for us over the past four years. We are confident that Brianna will continue to be a force for progress and success in her new role.
ChromaDex is entering an exciting period of growth and innovation! We are proud of our achievements in bringing Tru Niagen® and Niagen® to the market, and are now focusing on becoming operationally efficient to reach sustainable cash-flow break-even. Brianna Gerber, our CFO, is leading the team through this transition and is confident that we are on the right path for long-term success.
Prior to joining ChromaDex, Gerber held several executive positions at Mattel, Inc., where she specialized in Corporate Financial Planning and Investor Relations. She previously worked for 11 years at the Capital Group Companies, one of the world’s leading active asset managers. Gerber obtained her B.S. in Corporate Finance and Entrepreneurship from the University of Southern California and is now a Chartered Financial Analyst (CFA) and member of the CFA Society of Los Angeles.
ChromaDex is a revolutionary bioscience company that is changing the way we age. Our team of world-renowned scientists are at the forefront of research on NAD+ and its decline with age. We are the pioneers behind the NAD+ precursor, nicotinamide riboside, which is sold as the flagship product Niagen®. Our comprehensive patent portfolio protects our innovative products and research. We are giving a new meaning to healthy aging!
This release contains forward-looking statements that are based on our current expectations and estimates. We are closely monitoring the impact of the COVID-19 pandemic on our business and the global economy, as well as our history of operating losses and need to obtain additional financing. Additionally, we are closely tracking our product sales, our ability to maintain sales, marketing and distribution capabilities, and how consumer perceptions of our products are changing. Our reliance on a single or limited number of third-party suppliers also poses a risk to our business and financial condition. For more detailed information, we encourage readers to review ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex’s Quarterly Reports on Form 10-Q, and other filings submitted by ChromaDex to the SEC. We urge caution when considering these forward-looking statements, as actual results may differ from those suggested.